AI Article Synopsis
- The study aimed to explore how genetic variations affect efavirenz (EFV) levels and metabolism in HIV-infected Brazilians on specific antiretroviral treatments.
- Researchers collected blood samples from 82 HIV-positive adults on stable EFV regimens and analyzed both drug concentrations and genetic polymorphisms.
- Findings revealed significant individual differences in EFV levels, with about 70% of participants within the therapeutic range, while genetic variations explained a notable portion of the differences in drug metabolism.
Article Abstract
Aims: To investigate the influence of pharmacogenetic polymorphisms on efavirenz (EFV) exposure and metabolism in HIV-infected Brazilians under treatment with EFV-containing antiretroviral (ART) regimens.
Methods: HIV-positive adults (n = 82) on stable ART regimens containing 600 mg EFV once daily for at least 6 months were recruited at 2 university hospitals. Blood samples collected at mid-dose interval were used to quantify the plasma concentrations of EFV (denoted [EFV]), its major metabolite 8-OH-EFV ([8-OH-EFV]) and [8-OH-EFV]/[EFV] metabolic ratio, and to genotype single nucleotide polymorphisms in CYP2B6 (rs3745274, c.516G > T; rs28399499, c.983 T > C) and ABCB1 (rs3842, c.4036G > A). CYP2B6 metabolic phenotypes were inferred from the CYP2B6 diplotypes. Linear regression modelling was applied to identify sociodemographic, clinical and pharmacogenetic predictors of [EFV] and [8-OH-EFV]/[EFV] metabolic ratio.
Results: Wide (50-fold) interindividual variation in [EFV], [8-OH-EFV] and [8-OH-EFV]/[EFV] was observed; 69.5% of participants had [EFV] within the nominal therapeutic range (1000-4000 ng/mL), while 19.5 and 11.0% had [EFV] below and above this range, respectively. Multiple regression modelling retained only CYP2B6 metabolic phenotypes or the combined rs3745274 and rs28399499 genotypes, as significant predictors of [EFV] and [8-OH-EFV]/[EFV].
Conclusion: EFV exposure and disposition varied widely among HIV-infected Brazilians under stable treatment with EFV-containing ART regimens. About 1/10 of the participants had [EFV] exceeding nominal supratherapeutic concentration (4000 ng/mL), but reported tolerance to the ARV regimens, while 1/5 of participants had nominal subtherapeutic [EFV] (<1000 ng/mL) but adequate virological response. Genotype for the 2 CYP2B6 single nucleotide polymorphisms studied explained 48% of variation in [EFV] and 35% of variation in [8-OH-EFV]/[EFV].
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bcp.15387 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipid disturbances induced by psychotropic drugs: clinical and genetic predictors for early worsening of lipid levels and new-onset dyslipidaemia in Swiss psychiatric samples.
BJPsych Open
December 2024
Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland; Center for Research and Innovation in Clinical Pharmaceutical Sciences, University of Lausanne, Lausanne, Switzerland; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland; and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.
Article Synopsis
- Early worsening of plasma lipid levels (EWL), defined as a ≥5% change after one month, is linked to long-term lipid issues in patients treated with certain psychotropic medications.
- This study identified that low initial levels of total cholesterol, LDL-C, and triglycerides, along with high HDL-C levels, are significant risk factors for EWL, and integrating specific genetic variations (SNPs) can enhance prediction accuracy.
- Overall, clinical and genetic factors are important for predicting EWL and developing new-onset dyslipidaemia, suggesting the need for larger studies to improve these predictive models for clinical use.
Predictors of Selective Serotonin Reuptake Inhibitor Treatment Failure in Persons With Cystic Fibrosis.
Pediatr Pulmonol
November 2024
Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Introduction: Depression and anxiety are common in persons with cystic fibrosis (PwCF). Genetic polymorphisms in CYP2C19 and CYP2D6 are well-established predictors of selective serotonin reuptake inhibitors (SSRIs) treatment failure yet have not been studied specifically in PwCF. The purpose of this study was to determine the rate of SSRI failure in PwCF and to identify factors that predict treatment failure.
View Article and Find Full Text PDFTrends in and Predictors of Patient Pharmacogenomic Test Uptake in a National Healthcare System.
Genet Med
October 2024
Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA; William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA.
Purpose: Better understanding patient uptake of pharmacogenomic (PGx) testing may inform its implementation and maximize the benefits that such testing can confer. This study examined patient and provider factors associated with PGx test ordering in a national healthcare system where panel-based testing was implemented as part of routine care.
Methods: We used a retrospective matched cohort design and data from the Veterans Health Administration Corporate Data Warehouse.
Association of Gene Polymorphisms and Its Regulatory miRNAs with Methotrexate Toxicity in Children with Acute Lymphoblastic Leukemia.
Curr Issues Mol Biol
October 2024
Pediatric & Adolescent Hematology Oncology Unit, 2nd Pediatric Department Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital, S. Kiriakidi 1, 54636 Thessaloniki, Greece.
Methotrexate (MTX) is an anti-folate chemotherapeutic agent that is considered to be a gold standard in Acute Lymphoblastic Leukemia (ALL) therapy. Nevertheless, toxicities induced mainly due to high doses of MTX are still a challenge for clinical practice. MTX pharmacogenetics implicate various genes as predictors of MTX toxicity, especially those that participate in MTX intake like ().
View Article and Find Full Text PDFDopamine Transporter and Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study.
J Child Adolesc Psychopharmacol
December 2024
University of Washington, Seattle, Washington, USA.
Few biological or clinical predictors guide medication selection and/or dosing for attention-deficit/hyperactivity disorder (ADHD). Accumulating data suggest that genetic factors may contribute to clinically relevant pharmacodynamic (e.g.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!